Y mAbs Therapeutics Working Capital to Net Assets Ratio
Y mAbs Therapeutics working capital to net assets ratio. Y mAbs Therapeutics (YMAB) has a Working Capital to Net Assets ratio of 78.7% as of June 2025. Working capital of $68.84 Million (current assets of $91.79 Million minus current liabilities of $22.95 Million) is measured against net assets of $87.49 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Y mAbs Therapeutics to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Y mAbs Therapeutics (2016–2024)
Working capital to net assets ratio of Y mAbs Therapeutics from 2016 to 2024. This chart shows how Y mAbs Therapeutics's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 78.7%, reflecting working capital of $68.84 Million against net assets of $87.49 Million USD. See Y mAbs Therapeutics defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Y mAbs Therapeutics Working Capital to Net Assets Ratio by Year (2016–2024)
Y mAbs Therapeutics working capital to net assets ratio by year from 2016 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Y mAbs Therapeutics from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Y mAbs Therapeutics.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 81.3% | $74.81 Million | $92.00 Million | $98.51 Million | $23.70 Million | ▼ -8.8 pp |
| 2023 | 90.1% | $90.98 Million | $100.98 Million | $111.11 Million | $20.13 Million | ▼ -3.4 pp |
| 2022 | 93.5% | $102.16 Million | $109.22 Million | $130.45 Million | $28.28 Million | ▼ -3.3 pp |
| 2021 | 96.8% | $174.39 Million | $180.11 Million | $202.26 Million | $27.88 Million | ▼ -0.3 pp |
| 2020 | 97.2% | $102.83 Million | $105.84 Million | $122.36 Million | $19.54 Million | ▼ -2.6 pp |
| 2019 | 99.7% | $198.37 Million | $198.90 Million | $211.96 Million | $13.59 Million | ▼ -1.6 pp |
| 2018 | 101.3% | $142.41 Million | $140.53 Million | $151.53 Million | $9.12 Million | ▼ -0.2 pp |
| 2017 | 101.6% | $83.43 Million | $82.15 Million | $91.36 Million | $7.92 Million | ▼ -16.9 pp |
| 2016 | 118.4% | $14.29 Million | $12.06 Million | $17.26 Million | $2.98 Million | — |